Based on this hypothesis, and on the presence of S100A7 in the serum (Pasinetti, unpublished observation), we initiated a series of studies to test the feasibility of using S100A7 as a means of promoting non-amyloidogenic” α-secretase activity as potential novel therapeutic approach in AD. The gene discussed is S100A7; the disease is Alzheimer disease.